Hematopoietic stem cell transplant (HSCT) recipients have a high risk of acquiring invasive fungal infection (IFI) by virtue of cytopenias and receipt of therapies described. Survival analyses were performed on the basis of the type of the HSCT (allogeneic transplant from an unrelated or unmatched, related donor; or autologous transplant), the different IFIs (invasive candidiasis [IC] , invasive aspergillosis [IA], or IFI due to the Zygomycetes or other molds), and type of conditioning regimen (myeloablative vs. nonmyeloablative; for allogeneic HSCT recipients only).
We used logistic regression analysis to determine the major risk factors associated with 6-week mortality for allogeneic HSCT recipients with IA, excluding patients who received cord blood transplants. Risk factors evaluated for IA-associated mortality included the following variables: age, HSCT type (allogeneic transplant from an unrelated or unmatched, related donor), stem cell source (peripheral blood vs. bone marrow), conditioning regimen (myeloablative vs. nonmyeloablative), organ support (dialysis dependence or/and mechanical ventilation), cytomegalovirus infection, and disease risk ("high risk" was defined as acute or chronic lymphocytic leukemia, lymphoma, multiple myeloma, or acute myelogenic leukemia not in first remission; "low risk" was defined as all the rest of the hematologic malignancies). Different models were constructed on the basis of the interval between transplantation and diagnosis: one for early diagnosis of infection (р40 days after transplantation) and the other for late diagnosis of infection (140 days after transplantation). Because of the small number of patients, risk factor analysis for mortality was not performed for patients with IC or with IFI due to molds other than Aspergillus species.
Comparisons between categorical variables were performed by Fisher's exact test or the x 2 test; for continuous variables, Student's t test or analysis of variance was used. Survival distribution function was estimated using the Kaplan-Meier product-limit method. Bivariate analyses and cluster analysis were used to screen for potential mortality risk factors from a list of clinically significant variables; the final mortality risk factors were then determined through stepwise logistic regression with a .1 significant level.
RESULTS

Baseline patient characteristics.
Two hundred thirty-four adult HSCT recipients with a total of 250 proven or probable IFIs were included in this study. A total of 161 patients (68.8%) had received an allogeneic HSCT, and 73 (31.2%) had received an autologous HSCT. Among the allogeneic HSCT recipients, 63 (39.1%) patients had received an HLA-matched HSCT from a related donor, 59 (36.6%) had received an HLA-matched HSCT from an unrelated donor, 31 (19.3%) had received an HLA-mismatched HSCT, and 8 (5.0%) had received a haploidentical HSCT. Sixteen medical centers contributed a median of 5.5 patients each (range, 2-93 patients). Of note, 147 HSCT [2005] [2006] , the frequency of IC has decreased, whereas that of IFI due to Zygomycetes and other molds appears to have increased (data not shown). Aspergillus fumigatus was the most frequently isolated Aspergillus species (55 [37.2%] of 148 cases), whereas the species were not identified in 78 cases (52.7%) of IA. The diagnosis of IA was proven in 17 cases (11.5%) and was considered probable in 131 cases (88.5%). The galactomannan assay (in the serum and/or bronchoalveolar lavage fluid specimens) was used for diagnosis of 108 cases (73.0%) of IA. The majority of cases of IC were due to non-albicans species of Candida (47 [75.8%] of 62 cases); Candida glabrata was the most frequently isolated species (27 [43.5%] of 62 cases), and 7 cases (11.3%) were due to Candida krusei.
The interval between HSCT and diagnosis of IFI was studied for patients with a single IFI (figure 2). The median time after HSCT was 77 days (range, 0-2219 days) for IC and 82 days (range, 3-6542 days) for IA. There was a trend for IC to occur earlier after transplantation in autologous HSCT recipients (median interval, 28 days; range, 6-1559 days) than in allogeneic HSCT recipients (median interval, 108 days; range, 0-2219 days;
). In contrast, the interval between HSCT P p .11 and IA diagnosis for autologous HSCT recipients (median, 51 days; range, 3-2065 days) and allogeneic HSCT recipients (median, 83 days; range, 3-6542 days) did not appear to differ significantly ( ). IFI due to Zygomycetes and other P p .63 molds occurred late after HSCT (median interval, 173 days; range, 7-2254 days); it tended to occur later in autologous HSCT recipients (median interval, 412 days; range, 190-2254 days) than in allogeneic HSCT recipients (median interval, 162 days; range, 7-932 days;
). When the interval between P p .21 HSCT and IFI diagnosis was studied separately for the different allogeneic HSCT categories (matched, related donor vs. other), no major differences were observed (data not shown). Allogeneic HSCT recipients who received a myeloablative conditioning regimen were more likely to receive a diagnosis of IC early after HSCT (median interval, 65 days; range, 0-1594 days), compared with those who received a nonmyeloablative conditioning regimen (median interval, 590 days; range, 120-2219 days;
). In contrast, no major differences in the P p .26 interval between HSCT and diagnosis of IFI due to molds were observed between allogeneic HSCT recipients on the basis of their conditioning regimens (data not shown).
Antifungal therapy. Overall ). For patients with only 1 IFI, after exclusion P p .85 of patients who were lost to follow-up, IFI due to other molds was associated with the highest 12-week mortality rate (80.0% [12 of 15 patients]), followed by zygomycosis (64.3% [9 of 14 patients]) and IC (48.9% [22 of 45 patients]). Patients with IA had the lowest 12-week mortality rate in this study (35.5% [38 of 107 patients]). The 6-week survival rate was significantly better for HSCT recipients with IA, followed by those with IC and those with IFI due to Zygomycetes or other molds, who had the highest mortality rate ( ) ( figure 4A ). Response P ! .001 to treatment was assessed by investigators at 12 weeks after the diagnosis of IFI ( figure 4B ). The majority of HSCT recipients with IC (42 [67.7%] of 62 patients) and with IA (94 [63.5%] of 148 patients) were reported to have responded (completely or partially) to the administered therapy. In contrast, 10 (55.6%) of 18 patients with zygomycosis and 6 (35.3%) of 17 with IFI due to other molds demonstrated a worsening of their clinical status at follow-up.
In 6-week survival analyses performed for HSCT recipients with IA only, there were no significant differences observed in the survival rate based on the certainty of diagnosis (proven vs. probable), the HSCT type (allogenic vs. autologous), or the interval between HSCT and diagnosis (р40 days vs. 140 days; data not shown). However, there appeared to be a trend toward worse outcome at 6 weeks among allogeneic HSCT recipients with IA who received myeloablative conditioning ( ). P p .07 We performed bivariate analyses to assess risk factors for death at 6 weeks after the diagnosis of IA in allogeneic HSCT recipients; the variables examined are detailed in Methods. Nonmyeloablative conditioning ( ) and absence of me-P p .01 chanical ventilation or/and hemodialysis ( ) were asso-P p .01 ciated with improved survival rates. Because the variables examined were associated with the interval between HSCT and diagnosis, we performed separate analyses based on the timing of the diagnosis of IA. For the early time period (i.e., р40 days after transplantation), data on 30 patients with IA were included in bivariate and multivariate analyses. The bivariate 6-week exploratory analyses revealed trends toward improved survival associated with a lack of severe organ failure (as evidenced by dialysis and mechanical ventilation;
) and receipt of a P p .08 nonmyeloablative conditioning regimen ( ). When these P p .07 variables were introduced in a multivariate model, only severe organ dysfunction (OR, 1.60;
) continued to demon-P p .10 strate a trend toward higher mortality risk. Similarly, in bivariate analyses for late diagnoses (i.e., 140 days after transplantation), survival rates seemed to be better for patients who had received a nonmyeloablative condition regimen ( ) and P p .12 who did not require dialysis or/and mechanical ventilation ( ) . P p .02
DISCUSSION
We performed this multicenter, prospective, observational study to evaluate the contemporary epidemiologic characteristics, clinical presentations, and outcomes of IFI in 234 adult HSCT recipients during the period 2004-2007. Important findings include persistently high rates of IA, with possible improvements in IA-associated mortality, and poor outcomes associated with other fungal infection after HSCT.
Mortality rates for HSCT recipients with IA have historically been as high as 80%, although most studies were performed before the extensive use of voriconazole for the treatment of IA [3, 9, 10] . However, recent data suggest that outcomes appear to be improving [11] . We report 6-and 12-week mortality rates of 21.5% and 35.5%, respectively, among HSCT recipients with IA, which is markedly improved over rates from prior reports of outcomes during the 1990s. The observed 12-week survival rate is consistent with that reported by Herbrecht et al. [12] in the original validation trial of voriconazole for the treatment of IA, although only a minority of patients in that study had undergone HSCT. An analysis of that study suggested that assessment of clinical outcome and mortality at 6 weeks after diagnosis may be more reflective of IA-associated mortality [13] ; the 21.5% estimated mortality rate in our data set approximates the rates in prior studies reporting relatively recent outcomes and is likely to be a better estimate of attributable mortality. Improved contemporary outcomes likely reflect improved diagnostic and therapeutic modalities, compared with older patient series. In addition, it is likely that the potent and well-tolerated antifungal agents that are newly available have improved outcomes.
A number of host variables have been associated with both improved survival rates (e.g., nonmyeloablative conditioning regimens and use of peripheral blood as a stem cell source) and higher mortality (e.g., receipt of transplants from HLAmismatched donors, neutropenia, abnormal renal function, elevated bilirubin level, and use of corticosteroids) in allogeneic HSCT recipients with IA [11, 14] . In our study, receipt of a nonmyeloablative conditioning regimen and absence of severe organ failure appeared to be protective in bivariate analyses of 6-week mortality risk factors for allogeneic HSCT recipients with IA. Of note, only the absence of severe organ dysfunction 140 days after transplantation was significantly associated with improved outcome ( ), perhaps because of the small P p .02 number of patients included in these analyses.
More than one-half of the patients we describe were enrolled by only 2 institutions; this may have skewed the presented outcomes and created further biases. For instance, almost onehalf of the allogeneic HSCT recipients described in this study came from a single institution. When secondary survival analyses were performed that excluded the 93 patients who presented to that center, survival outcomes were similar to those observed in the overall patient population (data not shown). The majority of autologous HSCT recipients with an IFI (50 [68.5%] of 73 patients) were reported by a single center. Autologous HSCT recipients in this study had received a diagnosis of multiple myeloma (68.5%), had experienced a relapse of their underlying disease (60.3%), had a history of prior HSCT (56.2%), and had received corticosteroids (75.3%). This, in part, may have had an impact on the high number of cases of IA and the associated high mortality rate observed among autologous HSCT recipients in our study [15, 16] . Although differences in patient risks may, in part, explain this finding, there are obviously differences in clinical approaches and diagnostic aggressiveness between transplantation centers; these factors should be addressed in the design and conduct of future registries and clinical trials.
Although the frequency of IA remained relatively stable during 2005-2006, there seemed to be a trend toward higher numbers of IFIs due to Zygomycetes and other molds. This trend, first described in patients who received transplants after 1995, probably reflects the higher-risk transplantations performed (leading to a more immunosuppressed patient population) and the extensive use of prophylactic treatment with agents that have activity against Aspergillus species (e.g., voriconazole) [4, 9] . Availability of voriconazole as a therapeutic agent may also lead to diagnostic "bias," with innately resistant infections (zygomycosis) being diagnosed today; these infections may have been treated empirically with amphotericin B products in the 1990s. Of note, conventional amphotericin B was minimally used in this study. Because this reflects the practice observed in 16 different medical centers, it appears that conventional amphotericin B has largely been replaced by the lipid formulations of amphotericin B and the new third-generation azoles.
A shift toward late diagnosis of IA (i.e., 140 days after HSCT) among allogeneic HSCT recipients has been reported by multiple centers [3, 17, 18] . Almost two-thirds of IA cases among allogeneic HSCT recipients in this study were observed 140 days after transplantation. However, a number of IA cases among recipients of allogeneic (37.1%) and autologous (48.9%) HSCTs were observed р40 days after transplantation. This suggests that IA remains a significant problem soon after trans- plantation, despite the routine administration of prophylactic therapy and the aggressive monitoring of these patients. In accordance with already published data [9] , we found that IFI due to Zygomycetes or other molds remains a later complication for both allogeneic and autologous HSCT recipients.
Although the majority of patients with IC responded to the administered treatment, IC was associated with a 12-week mortality rate of 48.9%. We believe that this most likely reflects the underlying compromised immune status and organ function of patients who develop Candida infection; the true attributable mortality rate is unclear in this registry. Because of the small number of patients with IC in our study, we were not able to obtain data on potential risk factors associated with mortality in HSCT recipients with IC. IFIs due to Zygomycetes or other molds were associated with the highest mortality rates in our study (64.3% and 80.0%, respectively). This may be the result of the cumbersome, occasionally late diagnosis and suboptimal therapeutic modalities available for the management of these infections. Clearly, more studies need to be performed that address the diagnostic approaches to and treatment of IFI due to molds other than Aspergillus species.
This study has a number of limitations. Because of the design of this registry, the total number of transplants performed at each center is not recorded; thus, the incidences of the different IFIs cannot be calculated. Although this is a prospective data collection registry, the database is observational in nature and subject to a number of potential biases. Although data on antifungal therapy administered р30 days before diagnosis of the IFI were collected, it is not possible to clearly distinguish between prophylactic, preemptive, and empirical therapy. Information on supportive care of HSCT recipients at different centers was not available. In addition, information on the cytomegalovirus serostatus of donors and recipients was not reported. Finally, the results are limited to patients enrolled from selected centers in North America, and as such, they may not reflect practices from other parts of North America or around the globe.
Overall, we report that IA remains the most commonly identified IFI among HSCT recipients, although survival at 12 weeks has significantly improved. IFIs due to Candida species, Zygomycetes, and other molds were also observed and were associated with high mortality rates. As practices in the HSCT setting change, and as new diagnostic and therapeutic modalities are added to the armamentarium of clinicians, this field will continue to set challenges and require answers through future prospective, multiple-center studies.
